Taken together, our data suggest that the association of Chk1 or Wee1 inhibitors may represent a promising therapeutic approach in high-risk MM patients characterized by high CHK1 and WEE1 expression. This evidence concerns the gene CHEK1 and Miyoshi myopathy.